AIM ImmunoTech spotlights BioTuesdays feature on Ampligen

AIM ImmunoTech highlighted a BioTuesdays article on its strategy for Ampligen in metastatic pancreatic cancer. The company said it is working toward the next stage of clinical development after final Ampligen dosing in the DURIPANC trial.